Nanomedicine against multidrug resistance in cancer treatment

Nanomedicine

Volumn 7, Issue 4, 2012, Pages 465-468

  Gao, Jie ^a   Feng, Si Shen ^b   Guo, Yajun ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

chemotherapy; drug formulations; multidrug efflux pump proteins; nanocarriers; nanotechnology; P glycoproteins

Indexed keywords

ABC TRANSPORTER; ADENOSINE TRIPHOSPHATE; ALPHA TOCOPHEROL; BREAST CANCER RESISTANCE PROTEIN; DOXORUBICIN; GLYCOPROTEIN P; HYPOXIA INDUCIBLE FACTOR; I KAPPA B; POLOXAMER; PROTEIN BCL 2; VINCRISTINE;

APOPTOSIS; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; CELL POPULATION; CELL PROTECTION; CELL SURVIVAL; DNA REPAIR; DNA REPLICATION; DNA SYNTHESIS; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG FORMULATION; ENDOCYTOSIS; HUMAN; HYDROGEN BOND; INTRACELLULAR SIGNALING; MULTIDRUG RESISTANCE; NANOEMULSION; NANOMEDICINE; NANOTECHNOLOGY; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN STABILITY; REVIEW; RNA INTERFERENCE; TUMOR MICROENVIRONMENT; UPREGULATION;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; NANOMEDICINE;

EID: 84859458294     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.11     Document Type: Review

References (20)

1. Dong X, Mumper RJ. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond.) 5, 597-615 (2010).
2. Shapira A, Livney YD, Broxterman HJ. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist. Updat. 14, 150-163 (2011).
3. Dean M, Fojo T, Bates S. Tumor stem cells and drug resistance. Nat. Rev. Cancer 5, 275-284 (2005). (Pubitemid 40488633)
4. Reed JC. Bcl-2: prevention of apoptosis as a mechanism of drug resistance. Hematol. Oncol. Clin. North Am. 9, 451-473 (1995).
5. Shannon AM, Bouchier-Hayes DJ, Condron CM. Tumour hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat. Rev. 29, 297-307 (2003). (Pubitemid 37069660)
6. Chen AM, Zhang M, Wei D. Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the effcacy of chemotherapy in multidrug-resistant cancer cells. Small 5, 2673-2677 (2009).
7. Senchenkov A, Litvak DA, Cabot MC. Targeting ceramide metabolism-a strategy for overcoming drug resistance. J. Natl. Cancer Inst. 93, 347-357 (2001). (Pubitemid 32229379)
8. Meads MB, Gatenby RA, Dalton WS. Enviroment-mediated drug resistance: a major contributor to minimal residual disease. Nat. Rev. Cancer 9, 665-674 (2009).
9. Wion D, Berger F. Cancer stem cells. N. Engl. J. Med. 355, 1253-1261 (2006).
10. Greenberg PL, Lee SJ, Advani R: Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a Phase III trial (E2995). J. Clin. Oncol. 22, 1078-1086 (2004). (Pubitemid 41095041)
11. Feng SS, Zhao LY, Tang JT. Nanomedicine for oral chemotherapy. Nanomedicine (Lond.) 6(3), 407-410, 2011.
12. Gao J, Feng SS, Guo Y. Antibody engineering promotes nanomedicine for cancer treatment. Nanomedicine (Lond.) 5, 1141-1145 (2010).
13. Chow EK, Zhang XQ, Chen M. Nanodiamond therapeutic delivery agents mediate enhanced chemoresistant tumor treatment. Sci. Transl. Med. 3, 73ra21 (2011).
14. Minko T, Kopeckova P, Kopecek J. Comparison of the anticancer effect of free and HPMA copolymer-bound adriamycin in human ovarian carcinoma cells. Pharm. Res. 16, 986-996 (1999). (Pubitemid 29368143)
15. Song XR, Cai Z, Zheng Y. Reversion of multidrug resistance by coencapsulation of vincristine and verapamil in PLGA na noparticles. Eur. J. Pharm. Sci. 37, 300-305 (2009).
16. Ganta S, Amiji M. Coadministration of paclitaxel and curcumin in nanoemulsion formulations to overcome multidrug resistance in tumor cells. Mol. Pharm. 6, 928-939 (2009).
17. Tseng YC, Mozumdar S, Huang L. Lipid-based systemic delivery of siRNA. Adv. Drug Deliv. Rev. 61, 721-731 (2009).
18. Gao J, Yu Y, Zhang Y. EGFR-specifc PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma. Biomaterials 33, 270-282 (2012).
19. Gao J, Liu W, Xia Y. The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials 32, 3459-3470 (2011).
20. Yadav S, van Vlerken LE, Little SR. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother. Pharmacol. 63, 711-722 (2009).